Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMA ADMA Biologics	$16.73 -4.9%	$19.22	$10.21 ▼ $25.67	$3.99B	0.43	3.66 million shs	3.84 million shs
ANIP ANI Pharmaceuticals	$66.30 -2.6%	$62.88	$52.50 ▼ $77.00	$1.44B	0.57	320,722 shs	326,192 shs
EXAS Exact Sciences	$50.46 -3.4%	$54.33	$39.97 ▼ $72.83	$9.52B	0.95	2.57 million shs	2.15 million shs
LGND Ligand Pharmaceuticals	$139.10 +1.1%	$112.10	$90.29 ▼ $139.71	$2.68B	0.84	119,529 shs	347,058 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMA ADMA Biologics	0.00%	-9.62%	-7.72%	-21.49%	+25.88%
ANIP ANI Pharmaceuticals	0.00%	+2.06%	+2.54%	-4.20%	+5.27%
EXAS Exact Sciences	0.00%	-2.79%	-3.59%	+21.36%	+2.21%
LGND Ligand Pharmaceuticals	0.00%	+14.30%	+21.34%	+32.51%	+37.63%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMA ADMA Biologics	3.8714 of 5 stars	3.7	1.0	0.0	2.8	2.5	3.1
ANIP ANI Pharmaceuticals	3.9644 of 5 stars	2.5	1.0	3.3	3.8	3.3	1.3
EXAS Exact Sciences	4.7177 of 5 stars	3.5	5.0	4.7	3.2	2.5	0.6
LGND Ligand Pharmaceuticals	3.6705 of 5 stars	1.5	1.0	4.4	2.8	3.3	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMA ADMA Biologics	3.33	Buy	$27.67	65.37% Upside
ANIP ANI Pharmaceuticals	3.00	Buy	$78.88	18.97% Upside
EXAS Exact Sciences	2.95	Moderate Buy	$70.50	39.71% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$147.17	5.80% Upside

Current Analyst Ratings Breakdown

Latest LGND, ADMA, ANIP, and EXAS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	ANIP ANI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$84.00
7/8/2025	EXAS Exact Sciences	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$66.00 ➝ $68.00
6/24/2025	EXAS Exact Sciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $65.00
5/12/2025	ANIP ANI Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$86.00 ➝ $86.00
5/9/2025	LGND Ligand Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$142.00 ➝ $145.00
5/8/2025	ADMA ADMA Biologics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$25.00 ➝ $32.00
5/2/2025	EXAS Exact Sciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$55.00 ➝ $75.00
5/2/2025	EXAS Exact Sciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$52.00 ➝ $54.00
5/2/2025	EXAS Exact Sciences	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$60.00 ➝ $66.00
5/2/2025	EXAS Exact Sciences	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$69.00 ➝ $72.00
4/21/2025	ANIP ANI Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$62.00 ➝ $65.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMA ADMA Biologics	$426.45M	9.37	$0.54 per share	30.91	$1.48 per share	11.30
ANIP ANI Pharmaceuticals	$614.38M	2.34	$7.59 per share	8.73	$19.11 per share	3.47
EXAS Exact Sciences	$2.76B	3.45	$5.63 per share	8.96	$12.98 per share	3.89
LGND Ligand Pharmaceuticals	$167.13M	16.05	$1.61 per share	86.57	$43.95 per share	3.16

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMA ADMA Biologics	$197.67M	$0.85	19.68	24.25	N/A	45.01%	47.16%	30.51%	8/6/2025 (Estimated)
ANIP ANI Pharmaceuticals	-$18.52M	-$1.27	N/A	15.75	N/A	-3.12%	21.35%	7.52%	8/5/2025 (Estimated)
EXAS Exact Sciences	-$1.03B	-$5.51	N/A	100.92	10.77	-36.06%	-3.75%	-1.68%	8/6/2025 (Estimated)
LGND Ligand Pharmaceuticals	-$4.03M	-$7.12	N/A	37.49	N/A	-73.07%	-7.83%	-6.92%	8/5/2025 (Estimated)

Latest LGND, ADMA, ANIP, and EXAS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ADMA ADMA Biologics	$0.14	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	EXAS Exact Sciences	-$0.04	N/A	N/A	N/A	$774.43 million	N/A
8/5/2025	Q2 2025	ANIP ANI Pharmaceuticals	$1.49	N/A	N/A	N/A	$187.18 million	N/A
8/5/2025	Q2 2025	LGND Ligand Pharmaceuticals	$1.54	N/A	N/A	N/A	$43.87 million	N/A
5/9/2025	Q1 2025	ANIP ANI Pharmaceuticals	$1.37	$1.70	+$0.33	$0.69	$179.75 million	$197.12 million
5/8/2025	Q1 2025	LGND Ligand Pharmaceuticals	$1.23	$1.33	+$0.10	-$2.21	$37.84 million	$45.33 million
5/7/2025	Q1 2025	ADMA ADMA Biologics	$0.16	$0.14	-$0.02	$0.11	$116.40 million	$114.80 million
5/1/2025	Q1 2025	EXAS Exact Sciences	-$0.37	-$0.21	+$0.16	-$0.54	$688.58 million	$706.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
ANIP ANI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EXAS Exact Sciences	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMA ADMA Biologics	0.22	6.58	3.36
ANIP ANI Pharmaceuticals	1.46	2.66	1.98
EXAS Exact Sciences	0.97	2.73	2.38
LGND Ligand Pharmaceuticals	N/A	5.27	5.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADMA ADMA Biologics	75.68%
ANIP ANI Pharmaceuticals	76.05%
EXAS Exact Sciences	88.82%
LGND Ligand Pharmaceuticals	91.28%

Insider Ownership

Company	Insider Ownership
ADMA ADMA Biologics	3.50%
ANIP ANI Pharmaceuticals	11.10%
EXAS Exact Sciences	1.20%
LGND Ligand Pharmaceuticals	7.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMA ADMA Biologics	530	238.73 million	230.38 million	Optionable
ANIP ANI Pharmaceuticals	600	21.66 million	19.26 million	Optionable
EXAS Exact Sciences	7,000	188.64 million	186.37 million	Optionable
LGND Ligand Pharmaceuticals	80	19.29 million	17.94 million	Optionable

LGND, ADMA, ANIP, and EXAS Headlines

Recent News About These Companies

New York State Common Retirement Fund Increases Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

July 19 at 4:22 AM | marketbeat.com

Jackson Creek Investment Advisors LLC Trims Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

July 18 at 10:26 AM | marketbeat.com

Stocks Showing Rising Market Leadership: Ligand Pharmaceuticals Earns 84 RS Rating

July 18 at 9:24 AM | msn.com

Ligand Pharmaceuticals Stock Earns 84 RS Rating

July 17 at 11:20 PM | msn.com

J&J boosts full-year outlook on forex tailwinds and operational performance

July 16, 2025 | msn.com

Ligand Pharmaceuticals (NASDAQ:LGND) Reaches New 52-Week High - Still a Buy?

July 16, 2025 | marketbeat.com

Ligand Pharmaceuticals Shows Rising Price Performance With Jump To 82 RS Rating

July 15, 2025 | msn.com

CenterBook Partners LP Purchases 44,760 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

July 15, 2025 | marketbeat.com

Rice Hall James & Associates LLC Sells 7,704 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

July 14, 2025 | marketbeat.com

Principal Financial Group Inc. Acquires 3,284 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

July 14, 2025 | marketbeat.com

Stephens Investment Management Group LLC Reduces Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

July 13, 2025 | marketbeat.com

Ligand Pharmaceuticals Partner Pelthos Therapeutics Launches ... - Nasdaq

July 12, 2025 | nasdaq.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Director John W. Kozarich Sells 934 Shares

July 12, 2025 | insidertrades.com

Insider Sell Alert: John Kozarich Sells Shares of Ligand Pharmaceuticals Inc (LGND)

July 11, 2025 | gurufocus.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Director Sells $116,750.00 in Stock

July 11, 2025 | marketbeat.com

Ligand Pharmaceuticals Insider Trading Activity | NASDAQ:LGND | Benzinga

July 11, 2025 | benzinga.com

Ligand Pharmaceuticals: Ligand Partner Pelthos Therapeutics Launches ZELSUVMI

July 10, 2025 | finanznachrichten.de

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™

July 10, 2025 | globenewswire.com

Ligand Pharmaceuticals (NASDAQ:LGND) Shares Up 5% - Here's What Happened

July 9, 2025 | marketbeat.com

Calamos Advisors LLC Has $2.10 Million Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

July 6, 2025 | marketbeat.com

Ligand Pharmaceuticals Incorporated (LGND) - Yahoo Finance

July 5, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGND, ADMA, ANIP, and EXAS Company Descriptions

ADMA Biologics NASDAQ:ADMA

$16.73 -0.86 (-4.89%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$17.12 +0.39 (+2.33%)

As of 07/18/2025 07:55 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ANI Pharmaceuticals NASDAQ:ANIP

$66.30 -1.74 (-2.56%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$66.36 +0.06 (+0.08%)

As of 07/18/2025 04:33 PM Eastern

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Exact Sciences NASDAQ:EXAS

$50.46 -1.75 (-3.35%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$50.46 -0.01 (-0.01%)

As of 07/18/2025 06:30 PM Eastern

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Ligand Pharmaceuticals NASDAQ:LGND

$139.10 +1.53 (+1.11%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$139.14 +0.04 (+0.03%)

As of 07/18/2025 07:37 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time